REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Sierra MS, Forman D. Burden of colorectal cancer in Central and South America. Cancer Epidemiol. 2016;44 Suppl 1:S74-81.
3. Ríos JA, Barake MF, Arce MJ, et al. [The present situation of colorectal cancer in Chile]. Rev Med Chil. 2020;148:858-67.
4. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg. 2002;89:845-60.
5. Carballal S, Moreira L, Balaguer F. Serrated polyps and serrated polyposis syndrome. Cir Esp. 2013;91:141-8.
6. Shussman N, Wexner SD. Colorectal polyps and polyposis syndromes. Gastroenterol Rep (Oxf). 2014;2:1-15.
7. Mangas-sanjuan C, Jover R, Cubiella J, et al. Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update. Gastroenterol Hepatol (English Edition). 2019;42:188-201.
8. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467-80.
9. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095-105.
10. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-7.
11. Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116:458-79.
12. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol. 2015;110:72-90.
13. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672-82.
14. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017;S0168-8278(17)32294-8.
15. Chen W, Wang M, Jing X, et al. High risk of colorectal polyps in men with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35:2051-65.
16. Blackett JW, Verna EC, Lebwohl B. Increased prevalence of colorectal adenomas in patients with nonalcoholic fatty liver disease: a cross-sectional study. Dig Dis. 2020;38:222-30.
17. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
18. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Liver Int. 2020;40:1254-61.
19. Dulai PS, Sandborn WJ, Gupta S. Colorectal cancer and dysplasia in inflammatory bowel disease: a review of disease epidemiology, pathophysiology, and management. Cancer Prev Res (Phila). 2016;9:887-94.
20. Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69:620-5.
21. Johnson CM, Wei C, Ensor JE, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24:1207-22.
22. Dong Y, Liu Y, Shu Y, et al. Link between risk of colorectal cancer and serum vitamin E levels: a meta-analysis of case-control studies. Medicine (Baltimore). 2017;96:e7470.
23. Kobiela J, Dobrzycka M, Jędrusik P, et al. Metformin and colorectal cancer - a systematic review. Exp Clin Endocrinol Diabetes. 2019;127:445-54.
24. Dobrzycka M, Spychalski P, Łachiński AJ, Kobiela P, Jędrusik P, Kobiela J. Statins and colorectal cancer - a systematic review. Exp Clin Endocrinol Diabetes. 2020;128:255-62.
25. Guo CG, Ma W, Drew DA, et al. Aspirin use and risk of colorectal cancer among older adults. JAMA Oncol. 2021;7:428-35.
26. Lee S, Kim BG, Kim JW, et al. Obstructive sleep apnea is associated with an increased risk of colorectal neoplasia. Gastrointest Endosc. 2017;85:568-73.e1.
27. Niederseer D, Stadlmayr A, Huber-Schönauer U, et al. Cardiovascular risk and known coronary artery disease are associated with colorectal adenoma and advanced neoplasia. J Am Coll Cardiol. 2017;69:2348-50.
28. Lasa J, Rausch A, Bracho LF, et al. Colorectal adenoma risk is increased among recently diagnosed adult celiac disease patients. Gastroenterol Res Pract. 2018;2018:6150145.
29. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
30. Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and emerging biomarkers and imaging modalities for nonalcoholic fatty liver disease: clinical and research applications. Clin Ther. 2021;43:1505-22.
31. Hidalgo B, Goodman M. Multivariate or multivariable regression? Am J Public Health. 2013;103:39-40.
32. Seo JY, Bae JH, Kwak MS, et al. The risk of colorectal adenoma in nonalcoholic or metabolic-associated fatty liver disease. Biomedicines. 2021;9:1401.
33. Thune I, Allen K, Thompson RL, Wiseman MJ, Mitrou PN, McGinley-Gieser D. Abstract P3-10-06: what is the latest evidence on diet, nutrition, physical activity and cancer - key findings from the WCRF/AICR continuous update project. Cancer Res. 2018:78.
34. Chen X, Liang H, Song Q, Xu X, Cao D. Insulin promotes progression of colon cancer by upregulation of ACAT1. Lipids Health Dis. 2018;17:122.
35. Aslan A, Erdem H, Celik MA, Sahin A, Cankaya S. Investigation of insulin-like growth factor-1 (IGF-1), P53, and Wilms' tumor 1 (WT1) expression levels in the colon polyp subtypes in colon cancer. Med Sci Monit. 2019;25:5510-7.
37. Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74:478-97.
38. Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol. 2010;25:562-7.
39. Chen QF, Zhou XD, Sun YJ, et al. Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps. World J Gastroenterol. 2017;23:5206-15.
40. Chen J, Bian D, Zang S, et al. The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. Expert Rev Gastroenterol Hepatol. 2019;13:385-95.
41. Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38 Suppl 1:47-51.
42. López-Kostner F, Zárate AJ, Ponce A, et al. [Results of a multicentric colorectal cancer screening program in Chile]. Rev Med Chil. 2018;146:685-92.
43. Chakraborty D, Wang J. Nonalcoholic fatty liver disease and colorectal cancer: correlation and missing links. Life Sci. 2020;262:118507.
44. Gadaleta RM, Garcia-Irigoyen O, Moschetta A. Bile acids and colon cancer: is FXR the solution of the conundrum? Mol Aspects Med. 2017;56:66-74.
45. Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol Med. 2011;17:564-72.
46. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350-62.
